Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 6/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.39 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.39 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17070048 | 0.92 | NAAA (0.50) | DGKANAAAHTR2CEPHX1FAAH | |
| SCHEMBL16858346 | 0.88 | DGKA (0.47) | DGKANAAAHTR2CALDH1A1EPHX1 | |
| SCHEMBL12620065 | 0.86 | DGKA (0.57) | DGKANAAAHTR2CALDH1A1EPHX1 | |
| SCHEMBL27271810 | 0.85 | DGKA (0.60) | DGKANAAAHTR2CALDH1A1EPHX1 | |
| SCHEMBL20924890 | 0.84 | DGKA (0.53) | DGKAHTR2CALDH1A1DNM1EPHX2 | |
| SCHEMBL30566749 | 0.83 | NAAA (0.57) | DGKANAAAALDH1A1EPHX1FAAH | |
| SCHEMBL16466044 | 0.83 | DGKA (0.63) | DGKANAAAHTR2CALDH1A1EPHX1 | |
| SCHEMBL421653 | 0.83 | NAAA (0.60) | DGKANAAAHTR2CALDH1A1EPHX1 | |
| SCHEMBL5930623 | 0.83 | DGKA (0.60) | DGKANAAAHTR2CALDH1A1FAAH | |
| SCHEMBL591366 | 0.82 | NAAA (0.57) | DGKANAAAHTR2CEPHX1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3789411-A2 | POLYMER RESIN | Sumitomo Chemical Company, Limited (JP) | 2021-03-10 | — | — | EP | disclosed |
| EP-3492526-A1 | RESIN COMPOSITION AND USE THEREOF | Sumitomo Chemical Company Limited (JP) | 2019-06-05 | — | — | EP | disclosed |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-07-06 | — | — | US | disclosed |
| US-9598446-B2 | Amino compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239894-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | DGKA 4236/4885NAAA 4001/4885HTR2C 3149/4885 |
| US-20170189410-A1 | Amino Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, C9 | DGKA 4236/4885NAAA 4001/4885HTR2C 3149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.